Table 1 Selected published articles on immune-regulating therapeutic agents in preclinical development
From: The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications
Drugs | Indication | Therapeutic agents | Targets |
|---|---|---|---|
HCW-9302622 | Atherosclerosis | Peptide-fusion proteins | IL-2R Factor VIII |
Anti-CD45 antibody-drug conjugate628 | Atherosclerosis | Antibody-drug conjugates | CD45 |
Atherosclerosis | Chemical drugs | NOX | |
AZ-6983637 | Atherosclerosis | Small molecule drugs | α7nAChR |
VSB-16625 | Atherosclerosis | Monoclonal antibody | CCL4L1 |
CD40L/Mac-1 interaction inhibitors627 | Atherosclerosis | Antibody peptide | CD11b CD40LG ITGB2 |
BRP-187638 | Atherosclerosis | Chemical drugs | LOX5 FLAP |
Endothelial lipase inhibitors639 | Atherosclerosis | Chemical drugs | LIPG |
NLRP3 inflammasome inhibitor647 | Myocardial infarction | Chemical drugs | NLRP3 |
Myocardial infarction | Recombinant peptide | LGALS3 | |
SIM-339639 | Cerebral hemorrhage Myocardial infarction | Peptide-coupled drug | JNK |
RBB-004624 | Myocardial infarction | Antibody-fusion proteins | HSP70 |
TNAX-103A626 | Myocardial infarction | Humanized monoclonal antibodies | CD300A |
NWL-283631 | Myocardial infarction | Peptidomimetic drug | CASP3 |
Heart failure | Chemical drugs | S1PR | |
SR-9009645 | Myocardial infarction Heart failure | Chemical drugs | REV-ERB |
SA-12641 | Heart failure | Chemical drugs | MPO |
GDF15 modulator646 | Congestive heart failure | Chemical drugs | GDF15 |
CAR-T cells45 | Cardiac fibrosis | Adoptive T cell transfer | FAP |
In vivo-generated CAR T cells15 | Cardiac fibrosis | LNP-encapsulated modified mRNA | FAP |
